Key result
Centrally acting antihypertensive agents are effective for resistant and perioperative hypertension, but sustained-release moxonidine is associated with early mortality in heart failure.
Centrally acting antihypertensives remain useful in specific clinical scenarios like resistant or perioperative hypertension, though sustained-release moxonidine is contraindicated in heart failure due to increased mortality.
No takes yet. Share an insight, caveat, or question.
May support use in resistant or perioperative hypertension; leaves open need for randomized mortality data on other agents in heart failure.
Domenic A. Sica (2007) conducted a review in Hypertension. Centrally acting antihypertensive agents was evaluated. Centrally acting antihypertensive agents are effective for resistant and perioperative hypertension, but sustained-release moxonidine is associated with early mortality in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: